Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization.
Alexey Surov, Andreas Wienke, Jan Borggrefe, Timo Alexander Auer, Bernhard Gebauer, Aline Mähringer-Kunz, Felix Nensa, Johannes Haubold, Benedikt Michael Schaarschmidt, René Hosch, Jens Kleesiek, Thierno D Diallo, Natascha Roehlen, Dominik Bettinger, Michel Eisenblätter, Verena Steinle, Philipp Mayer, David Zopfs, Daniel Pinto Dos Santos, Lukas Müller, Roman Kloeckner
{"title":"Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization.","authors":"Alexey Surov, Andreas Wienke, Jan Borggrefe, Timo Alexander Auer, Bernhard Gebauer, Aline Mähringer-Kunz, Felix Nensa, Johannes Haubold, Benedikt Michael Schaarschmidt, René Hosch, Jens Kleesiek, Thierno D Diallo, Natascha Roehlen, Dominik Bettinger, Michel Eisenblätter, Verena Steinle, Philipp Mayer, David Zopfs, Daniel Pinto Dos Santos, Lukas Müller, Roman Kloeckner","doi":"10.1007/s00432-024-06043-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of the present study was to analyze associations between different skeletal muscle quality parameters and survival in patients with hepatocellular carcinoma (HCC) undergoing treatment with transarterial chemoembolization (TACE).</p><p><strong>Methods: </strong>We retrospectively enrolled 784 treatment-naïve patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. Intramuscular adipose tissue (IMAT) and skeletal muscle density (SMD) were estimated. Myosteatosis was defined as SMD < 28.0 HU for men and < 23.8 HU for women. Furthermore, albumin-SMD score (ADS) was calculated as follows: serum albumin (g/dL) × SMD (HU). To assess the impact of muscle quality on survival, Cox regression model was used. Kaplan-Meier curves were used for survival analysis. Parameters of skeletal muscle quality were compared in univariate and multivariate regression analyses, adjusted for established risk factors.</p><p><strong>Results: </strong>In the overall sample, survivors had higher SMD and ADS in comparison to non-survivors. Patients with low ADS had a lower OS than patients with high ADS (8.4 vs. 14.3 months, p < 0.001). In alcohol-induced HCC, none of the analyzed parameters of muscle quality influenced survival. In viral induced HCC, patients with low ADS had lower OS than patients with high ADS (8.8 vs. 15.7 months, p < 0.001). In patients with non-alcoholic steatohepatitis (NASH), none of the analyzed parameters of muscle quality influenced survival.</p><p><strong>Conclusions: </strong>Low ADS is an independent predictor of worse OS in patients with viral-induced HCC undergoing treatment with TACE. In alcohol-induced and NASH-induced HCCs, parameters of muscle quality do not influence OS.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"150 12","pages":"515"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00432-024-06043-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The purpose of the present study was to analyze associations between different skeletal muscle quality parameters and survival in patients with hepatocellular carcinoma (HCC) undergoing treatment with transarterial chemoembolization (TACE).
Methods: We retrospectively enrolled 784 treatment-naïve patients with HCC undergoing TACE at six tertiary care centers between 2010 and 2020. Intramuscular adipose tissue (IMAT) and skeletal muscle density (SMD) were estimated. Myosteatosis was defined as SMD < 28.0 HU for men and < 23.8 HU for women. Furthermore, albumin-SMD score (ADS) was calculated as follows: serum albumin (g/dL) × SMD (HU). To assess the impact of muscle quality on survival, Cox regression model was used. Kaplan-Meier curves were used for survival analysis. Parameters of skeletal muscle quality were compared in univariate and multivariate regression analyses, adjusted for established risk factors.
Results: In the overall sample, survivors had higher SMD and ADS in comparison to non-survivors. Patients with low ADS had a lower OS than patients with high ADS (8.4 vs. 14.3 months, p < 0.001). In alcohol-induced HCC, none of the analyzed parameters of muscle quality influenced survival. In viral induced HCC, patients with low ADS had lower OS than patients with high ADS (8.8 vs. 15.7 months, p < 0.001). In patients with non-alcoholic steatohepatitis (NASH), none of the analyzed parameters of muscle quality influenced survival.
Conclusions: Low ADS is an independent predictor of worse OS in patients with viral-induced HCC undergoing treatment with TACE. In alcohol-induced and NASH-induced HCCs, parameters of muscle quality do not influence OS.
目的：本研究的目的是分析经动脉化疗栓塞（TACE）治疗的肝细胞癌（HCC）患者不同骨骼肌质量参数与生存之间的关系。方法：我们回顾性地纳入了2010年至2020年间在6个三级医疗中心接受TACE治疗的784例treatment-naïve HCC患者。估计肌内脂肪组织（IMAT）和骨骼肌密度（SMD）。结果：在总体样本中，与非幸存者相比，幸存者的SMD和ADS更高。低ADS患者的OS低于高ADS患者（8.4 vs 14.3个月）。结论：低ADS是接受TACE治疗的病毒诱导的HCC患者OS恶化的独立预测因子。在酒精诱导和nash诱导的hcc中，肌肉质量参数不影响OS。
期刊介绍：
The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses.
The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
